News | Soractelite

Home
Benign Prostatic Hyperplasia
SoracteLite
News
Company
Contact Us

Select Page

Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia: A Feasibility Study.

Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia: A Feasibility Study.

May 8, 2017

UroToday Read the article here

Next Entries »

Search

Search for:

Archive

Legal Notes
Privacy and Cookies Policy
Information for Customers and Suppliers

REGULATORY NOTICE USA

EchoLaser X4 is FDA cleared (510K) for tissue ablation in urology. Indications for use are however not disease specific. Although there’s solid clinical evidence, generated by a multitude of published clinical trials, confirming safety and efficacy of the treatment, patients must always discuss treatment options with a specialist doctor. It will ultimately be the specialist doctor who will determine if a patient is eligible for EchoLaser treatment.

© 2018 SoracteLite is a registered trademark in European Union by: Elesta SpA – tel.+39 055 88 26 807 – fax.+39 055 7766698
info@elesta-echolaser.com

The information published in this website is of general nature and only have an informative purpose. Under no circumstances can they replace any treatment or therapy prescribed by a physician or other healthcare professionals authorised by law. Any information on medical procedures and treatment descriptions in this website are intended for informative purposes only and do not provide the knowledge required for their application. All the indications provided at www.soractelite.info must always be backed up by the opinion of your doctor.

This site uses cookies to provide you with a better browsing experience. By accepting this banner, scrolling down this page, clicking on a link or continuing to browse in any other way, you consent to the use of cookies. If want to know more read our cookie policy. Accept Read the policy